Home » Stocks » LIFE

aTyr Pharma, Inc. (LIFE)

Stock Price: $3.55 USD -0.04 (-1.11%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $3.65 +0.10 (2.82%) Nov 27, 2:53 PM

Stock Price Chart

Key Info

Market Cap 36.16M
Revenue (ttm) 8.55M
Net Income (ttm) -17.27M
Shares Out 10.19M
EPS (ttm) -2.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $3.55
Previous Close $3.59
Change ($) -0.04
Change (%) -1.11%
Day's Open 3.64
Day's Range 3.52 - 3.70
Day's Volume 46,385
52-Week Range 2.13 - 7.62

More Stats

Market Cap 36.16M
Enterprise Value 5.51M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 10.19M
Float n/a
EPS (basic) -2.60
EPS (diluted) -2.32
FCF / Share -1.56
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 68,994
Short Ratio 1.29
Short % of Float n/a
Beta 1.97
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.23
PB Ratio 1.14
Revenue 8.55M
Operating Income -16.93M
Net Income -17.27M
Free Cash Flow -15.04M
Net Cash 30.65M
Net Cash / Share 3.01
Gross Margin -159.44%
Operating Margin -198.14%
Profit Margin -202.00%
FCF Margin -176.01%
ROA -24.79%
ROE -59.35%
ROIC -81.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$13.50*
(280.28% upside)
Low
12.0
Current: $3.55
High
15.0
Target: 13.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue0.42------
Gross Profit0.42------
Operating Income-22.98-32.82-47.15-57.94-47.62-23.55-19.54
Net Income-23.60-34.52-48.21-57.86-47.97-24.35-20.01
Shares Outstanding3.362.141.851.691.130.060.05
Earnings Per Share-7.03-16.11-26.13-34.16-42.42-415.65-397.45
Operating Cash Flow-20.01-31.06-42.36-52.86-36.80-22.82-17.31
Capital Expenditures-0.03-0.59-1.31-0.60-0.66-0.25-0.64
Free Cash Flow-20.04-31.66-43.68-53.46-37.46-23.07-17.96
Cash & Equivalents31.1449.5585.1272.1595.5415.8536.46
Total Debt11.7316.0319.739.545.1410.286.89
Net Cash / Debt19.4133.5265.3962.6190.395.5829.57
Assets36.1952.7589.3680.5213020.6439.79
Liabilities15.1619.1025.1117.7214.63112106
Book Value21.1933.6564.2562.80115-91.01-68.50
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name aTyr Pharma, Inc.
Country United States
Employees 39
CEO Sanjay S. Shukla

Stock Information

Ticker Symbol LIFE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LIFE
IPO Date May 7, 2015

Description

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Company for the development and commercialization of ATYR1923 for ILDs in Japan; and a research collaboration with the Medical University of South Carolina to develop therapeutic antibodies that selectively target specific NRP2 isoforms. The company was founded in 2005 and is headquartered in San Diego, California.